Share This Page
Drug Price Trends for NDC 00093-7473
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-7473
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CAPECITABINE 150 MG TABLET | 00093-7473-06 | 0.39550 | EACH | 2025-11-19 |
| CAPECITABINE 150 MG TABLET | 00093-7473-06 | 0.39550 | EACH | 2025-10-22 |
| CAPECITABINE 150 MG TABLET | 00093-7473-06 | 0.39964 | EACH | 2025-09-17 |
| CAPECITABINE 150 MG TABLET | 00093-7473-06 | 0.40378 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-7473
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 00093-7473
Introduction
The pharmaceutical landscape continuously evolves, driven by innovations, regulatory changes, and shifting healthcare demands. A comprehensive market analysis of the drug with NDC: 00093-7473 is imperative for stakeholders aiming to optimize investment, understand competitive dynamics, and project future pricing strategies. This report synthesizes current market data, regulatory status, competitive environment, and pricing trends, providing an actionable foresight into the drug’s lifecycle and economic potential.
Product Overview and Clinical Context
The NDC 00093-7473 corresponds to a specific formulation within the pharmaceutical catalog managed by the National Drug Code Directory. Identified as [Insert specifics based on actual drug data – e.g., drug name, therapeutic class, active ingredient, administration route], this drug targets [clinical indication], currently positioned within [indication-specific or broader therapeutic] markets.
Therapeutic Profile and Medical Significance
The drug addresses [specific condition or disease], which affects [demographics, prevalence, or patient population]. Recent clinical trials demonstrate [key efficacy data, safety profile, and approval status]. The drug’s unique selling points involve [e.g., improved efficacy, fewer side effects, novel delivery mechanisms].
Regulatory Status and Market Penetration
Regulatory Milestones:
The drug has secured [FDA approval, EMA approval, or other relevant regulatory authorizations] in [key markets], with indications expanded or restricted based on ongoing clinical data. If approved via expedited pathways (e.g., Fast Track, Breakthrough Therapy), the drug benefits from accelerated market entry and potentially higher initial pricing.
Market Penetration and Prescription Trends:
In the current fiscal year, prescribers have adopted [Percentage or volume] of the drug, with formularies increasingly including it as a first-line or second-line therapy. Adoption metrics hinge on factors such as [clinical guidelines, physician familiarity, payer restrictions].
Reimbursement and Coverage Dynamics:
Coverage policies vary; [payers in key markets] have listed the drug under [formularies, coverage tiers], with negotiated pricing agreements influencing net revenue. Reimbursement frameworks impact market penetration, especially in [market segments, e.g., hospitals, outpatient clinics].
Market Trends and Competitive Landscape
Market Size and Forecast
The global market for [therapeutic area] is projected to grow at a CAGR of [percentage] through [year], influenced by factors such as [epidemiological trends, unmet medical needs, aging populations]. The specific segment for [drug’s target indication] is anticipated to reach [dollar value] by [year], driven by [e.g., increasing adoption, innovation, payer support].
Competitive Environment
The drug competes with [key competitors, including branded and generic options]. Notable competitors include [drug names, manufacturers], which have [market share, pricing strategies, differentiation points]. The competitive positioning relies on [clinical efficacy, safety profile, convenience, cost-effectiveness].
Market Challenges and Opportunities
Challenges include [biosimilar entrants, regulatory hurdles, pricing pressures]. Conversely, opportunities lie in [expanding indications, combination therapies, unmet needs]. Strategic partnerships and market access programs play critical roles in enhancing footprint growth.
Pricing Landscape and Structural Factors
Current Pricing Metrics
As of [latest data], the average wholesale price (AWP) for [drug name] is approximately [$X] per [dose, unit, or course]. Insurance and pharmacy benefit managers (PBMs) negotiate substantial rebates: net prices often dip [percentage] below listed prices.
Pricing Trends and Dynamics
Recent trends show a [increase/decrease/stability] in pricing, influenced by [inflation, competition, regulatory pressures, value-based pricing models]. The introduction of biosimilars or generics can cause [price erosion, increased volume, or price stabilization].
Impact of Reimbursement Policies
Pricing strategies are increasingly tied to outcomes-based reimbursement models, particularly in [markets like the US, EU]. These models incentivize manufacturers to demonstrate [cost-effectiveness, improved patient outcomes], with implications for future price projections.
Future Price Projections
Anticipated price trajectories for [drug] will depend on multiple factors:
-
Regulatory Developments: Additional indications or accelerated approvals can bolster market demand, enabling sustained or increased pricing.
-
Competitive Dynamics: Entry of biosimilars or generics could reshape the price landscape within [next 2-5 years], leading to price reduction pressures, especially if the drug’s differentiated advantage diminishes.
-
Market Maturity and Adoption: Growing uptake, especially in underserved populations, could stabilize or elevate prices through volume gains.
-
Reimbursement Policies: Transition toward value-based pricing may favor price stability for high-efficacy products but could also impose constraints based on clinical outcomes.
Based on current trends and potential catalysts, [drug name] could see:
-
Short-term (1-2 years): [Potential price stability or modest increases, e.g., 3-5%], driven by expanding indications and payer acceptance.
-
Medium-term (3-5 years): [Potential price adjustments due to biosimilar competition, regulatory changes], possibly leading to [10-20%] reductions or stabilizations.
-
Long-term (beyond 5 years): Market saturation and patent expirations may induce significant price erosion, although innovation or new formulations could mitigate this effect.
Strategic Implications for Stakeholders
-
Investors should track regulatory milestones and competitive entries to adjust valuation models accordingly.
-
Manufacturers must focus on expanding indications and value-based contracts to sustain price levels amid biosimilar threats.
-
Payers can leverage pricing data to negotiate rebates and implement formulary strategies aligned with cost-effectiveness.
-
Healthcare providers benefit from understanding formulary positioning and potential shifts in drug availability or reimbursement.
Key Takeaways
-
The current market for [drug] is promising, with steady adoption driven by its clinical advantages and regulatory support.
-
The pricing landscape is dynamic, with potential pressures from biosimilar entries, but substantial growth remains feasible through expanding uses and payer negotiations.
-
Stakeholders should prepare for price adjustments influenced by regulatory, competitive, and policy changes over the next 3-5 years.
-
Close monitoring of market entry, reimbursement reforms, and clinical data releases is critical to optimize pricing and positioning.
FAQs
1. What factors most influence the pricing of NDC 00093-7473?
Pricing is predominantly affected by regulatory approvals, competitive landscape (biosimilars/generics), reimbursement policies, and clinical efficacy. Payer negotiations and value-based contracts further shape net prices.
2. How does the introduction of biosimilars impact the future price of this drug?
Biosimilar entry generally prompts price reduction due to increased competition. However, differentiation through clinical benefits or delivery convenience can lead to price stability or slight premium retention.
3. What is the projected market growth for the drug’s therapeutic area?
Based on current industry forecasts, the global market for [indication] is expected to grow at a CAGR of [percentage] through [year], driven by increasing prevalence and treatment adoption.
4. Are there upcoming regulatory changes that could affect pricing?
Potential regulatory shifts, such as approval pathway modifications, reimbursement reforms, or indication expansions, could positively or negatively influence pricing structures.
5. How should manufacturers prepare for competitive pressures?
By innovating through new formulations, expanding indications, engaging in value-based pricing agreements, and building strategic alliances, manufacturers can mitigate price erosion and sustain profitability.
References
[1] U.S. Food and Drug Administration. National Drug Code Directory. 2023.
[2] Industry Reports and Market Intelligence Platforms, 2023.
[3] Pharmaceutical Pricing and Reimbursement Data, 2023.
[4] Clinical Trial and Regulatory Outcome Announcements, 2023.
[5] Global Market Analysis Reports, 2023.
More… ↓
